-
Dinaciclib (SCH-727965) is an
experimental drug that
inhibits cyclin-dependent
kinases (CDKs). It is
being evaluated in
clinical trials for
various cancer...
-
currently being evaluated in
phase II
trials for
hepatocellular carcinoma.
Dinaciclib- a pan-CDK
inhibitor against CDK1, CDK2, CDK5, and CDK9. As of December...
-
dimiracetam (INN)
dimoxaprost (INN)
dimoxyline (INN)
dimpylate (INN)
dinaciclib (USAN, INN)
dinalin (INN)
dinazafone (INN)
diniprofylline (INN) dinitolmide...
- Nathanson, K.L., Smalley, K.S.M., Herlyn, M.: The anti-melanoma
activity of
dinaciclib, a cyclin-dependent
kinase inhibitor, is
dependent on p53 signaling. PLoS...
-
cells with the PKC-specific
inhibitor Gö-6983 or the pan-CDK
inhibitor dinaciclib.
These findings indicate, that site-specific
phosphorylation mediated...
